

MEMO

To: Healthcare Professionals Offering COVID-19, Influenza and RSV Vaccine

From: Dr. Janice Fitzgerald, Chief Medical Officer of Health

Date: October 2, 2026

Re: COVID-19, Influenza and RSV Vaccine Information for 2026-27 Season

The 2026-27 Influenza and COVID-19 immunization campaign will begin October 19, 2026. Vaccine for the publicly funded program is now available for distribution to community-based physician's offices, community health nursing clinics, pharmacies, health facilities, staff health offices, and other healthcare professionals who are offering influenza immunizations through the publicly funded system this season.

COVID-19 Vaccine

In June 2026, the National Advisory Committee on Immunization (NACI) provided [guidance on the use of COVID-19 vaccines for 2026-27](#). All individuals aged 6 months and older, regardless of prior vaccination status, are eligible for COVID-19 vaccination this Fall.

Vaccination is strongly recommended for those at higher risk of exposure to COVID-19 or severe illness, including:

- Adults 65+
- Residents of long-term care or senior congregate living settings
- Individuals with [underlying medical conditions](#), including children with complex needs
- Pregnant individuals
- People from First Nations, Métis, and Inuit communities
- Members of racialized or equity-denied groups
- Health care workers and caregivers

A second dose, spaced at least 3 months after the first, is recommended for:

- Adults 80+
- Residents of long-term care
- Individuals 6 months and older who are [moderately to severely immunocompromised](#)
- Adults 65 to 79 years of age with [underlying medical conditions](#) that place them at higher risk of severe COVID-19

Adults 65–79 may also receive a second dose based on individual risk and clinical judgment.

For previously vaccinated individuals, a minimum interval of 3 months between COVID-19 vaccine doses is recommended.

Recommendations for those not previously vaccinated against COVID-19:

Age at time of immunization	Immunization schedule	Products available	Minimum interval
Immunocompetent Individuals			
6 months to under 5 years of age	2 doses for primary series 1 dose if previously vaccinated	Moderna Spikevax 25mcg (multi-dose vial)	8 weeks
5-11 years of age	1 dose	Moderna Spikevax 25mcg (multi-dose vial)	Not applicable
12 years of age and older	1 dose	Moderna Spikevax 50mcg (multi-dose vial or pre-filled syringe) Pfizer Comirnaty 30mcg (pre-filled syringe)	Not applicable
Immunocompromised Individuals			
6 months to under 5 years of age	3 doses	Moderna Spikevax 25mcg (multi-dose vial)	4-8 weeks
5-11 years of age	2 doses*	Moderna Spikevax 25mcg (multi-dose vial)	4-8 weeks
12 years of age and older	2 doses*	Moderna Spikevax 50mcg (multi-dose vial or pre-filled syringe) Pfizer Comirnaty 30mcg (pre-filled syringe)	4-8 weeks

*New recipients of haematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR) T-cell therapy should be vaccinated with 3 doses beginning at 3 to 6 months post-HSCT/CAR T-cell therapy, regardless of vaccination or infection history. For HSCT and CAR T-cell recipients, the recommended interval between doses is 4 to 8 weeks.

The table below outlines the shelf-life requirements for each:

	Pfizer-BioNTech Comirnaty mRNA Vaccine	Moderna Spikevax mRNA Vaccine	
	Pre-filled Syringe	Multi-dose Vial	Pre-filled Syringe
Storage	Prefilled syringes can be stored at 2°C to 8°C until the expiration date After removing the tip cap and attaching an appropriate needle, the prefilled syringes should be used immediately. If it cannot be used immediately, it must be used within 4 hours. Do not freeze	Frozen (-50°C to -15°C): until expiry date noted on carton/vial 2°C to 8°C: 60 days Room temperature: before first puncture: 12 hours after first puncture: a total of 12 hours of room temperature exposure Do not refreeze once thawed	Frozen (-50°C to -15°C): until expiry date noted on carton/vial/syringe 2°C to 8°C: 60 days Room temperature: 12 hours Do not refreeze once thawed

For more information on vaccine stability, please visit the [Vaccine Storage and Handling Factsheet](#).

A small quantity of Novavax Nuvaxovid COVID-19 vaccine will also be available for individuals that are unable to receive mRNA vaccine. Nuvaxovid COVID-19 vaccine will be accessible through the provincial public health depot for public health use only. Nuvaxovid is authorized for individuals 12 years of age and older. It is available in pre-filled syringe format and stable at 2°C to 8°C until the expiry date identified on the syringe. NL Health Services depot clerks can connect with the provincial vaccine depot for access to Nuvaxovid vaccine.

Influenza Vaccine

Influenza vaccine is available to all individuals 6 months of age and older. Emphasis should be placed on immunizing those who are at increased risk for complications from influenza, and individuals who are capable of transmitting influenza to individuals at high risk of a severe influenza infection.

Those at higher risk of exposure to influenza or severe influenza disease include:

- All pregnant people.
- Adults and children with the following chronic health conditions:
 - Cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis & asthma);
 - Diabetes mellitus and other metabolic diseases;
 - Cancer, immune compromising conditions (due to underlying disease and/or therapy);
 - Renal disease;
 - Anemia or hemoglobinopathy;
 - Neurologic or neurodevelopment conditions;
 - BMI ≥ 40 ;
 - Children and adolescents (age 6 months to 18 years) undergoing treatment for long periods with acetylsalicylic acid, because of the potential increase of Reye's syndrome associated with influenza.
- People of any age who are residents of nursing homes and other chronic care facilities.
- People ≥ 65 years of age.
- All children 6 to 59 months of age.
- Indigenous Peoples

People in contact with individuals at high risk of complications from influenza, include:

- Health care and other care providers in facilities and community settings who, through their activities, are in contact with those at high risk of influenza complications.
- Household contacts (adults and children) of individuals at high risk of influenza-related complications (even if the individual at high risk has been immunized):
- Household contacts of individuals at high risk, as listed in the section above;
- Household contacts of infants < 6 months of age as these infants are at high risk of complications from influenza but cannot receive influenza vaccine; and
- Members of a household expecting a newborn during the influenza season.
- Those providing regular childcare to children ≤ 59 months of age, whether in or out of the home.
- Those who provide services within closed or relatively closed settings to persons at high risk.

Other groups recommended to receive influenza vaccine:

- People who provide essential community services.
- People who are or could be involved in culling operations of poultry infected with avian influenza

For the 2026-27 season, the following trivalent influenza vaccine products are being offered to the public:

Age category	Recommended Influenza vaccine
6 months to 64 years of age	Fluviral or Fluzone (multi-dose vial and pre-filled syringe)
65 years of age and older	Fluad (pre-filled syringe)

Children 6 months and older to less than 9 years of age receiving influenza vaccine for the first time are recommended to receive 2 doses of vaccine spaced at least 4 weeks apart. Children 6 months and older to less than 9 years of age who have been vaccinated in the past should receive one dose of influenza vaccine per season thereafter.

See the [National Advisory Committee on Immunization \(NACI\) recommendations](#) for more information.

NACI has concluded that egg allergic individuals may be vaccinated against influenza using inactivated TIV, without prior influenza vaccine skin test and with the full dose, irrespective of a past severe reaction to egg.

Unopened vials and pre-filled syringes of Influenza vaccine are stable at 2°C to 8°C until the expiry date printed on label. Once punctured, multidose vials must be discarded after 28 days.

RSV Vaccine

Respiratory syncytial virus (RSV) infection is a major cause of lower respiratory tract illness, particularly among infants, young children, and older adults at higher risk for RSV. In Newfoundland and Labrador, while RSV can be detected throughout the entire year, the highest number of infections often occur between the months of November and May.

RSV vaccine is offered through the provincial publicly funded system to the following populations:

- Adults 60 years of age and older living in senior congregate living facilities
- Adults 75 years of age and older

Two products will be available within the province for protection against RSV in adult populations; Arexvy and mResvia, both in pre-filled syringe format. See the [RSV NACI statement](#) for more information.

- Arexvy is stable at 2°C to 8°C until the expiry date noted on the syringe.
- mResvia vaccine is stable at 2°C to 8°C for 90 days following removal from frozen storage.

Your vaccine depot clerk will provide expiry date information. COVID-19, Influenza and RSV vaccine can be given at the same time as, or any time before or after, other vaccines, including live, non-live, adjuvanted or unadjuvanted vaccines for individuals 6 months of age and older.

Vaccine Ordering

The distribution and supply of vaccine will be monitored closely by public health staff within the Department of Health and Community Services (HCS) and NL Health Services (NLHS). Orders will be filled to the best of their ability. Please have measures in place to reduce wastage. It is imperative you do not overstock vaccine because this could lead to vaccine wastage.

When ordering vaccine, providers will need to ensure they are ordering and utilizing vaccines based on the appropriate age recommendations for each products' use. Before placing an order, ensure there is sufficient storage capacity of all products. The [Provincial Publicly Funded Vaccine Order Form](#) is available on governments website.

Vaccine viability may be compromised if not stored properly. Insulated coolers and sufficient supply of ice packs will be required when picking up vaccine. Vaccine will not be released without the proper equipment for transportation.

Supplies needed to administer vaccine will be provided to all healthcare professionals administering RSV, influenza and COVID-19 immunizations. To order vaccine supplies, complete the [Vaccine Supply Order Form](#) and email it to: vaccination.supplies@nlhealthservices.ca

Vaccine must be stored properly in the clinic environment to ensure it remains at the appropriate temperature. Please see the [Vaccine Storage and Handling Factsheet](#) for more information.

For more information on these vaccines, including product monographs, please visit [Time For The Shot - Government of Newfoundland and Labrador](#).

Adverse Events Following Immunization

All Adverse Events Following Immunization (AEFIs) are to be reported to the public health. For more information, please refer to the [provincial immunization manual](#). The national AEFI form can be accessed [here](#).